Blockchain Registration Transaction Record

NanoViricides Gets Ethics Nod for Ebola Oral Gummies Trial in DRC

NanoViricides receives ethics approval for Phase II trial of NV-387 oral gummies for Bundibugyo ebolavirus in DRC, offering potential oral treatment for Ebola.

This news matters because the current Bundibugyo ebolavirus outbreak in the DRC lacks approved therapies or vaccines. NanoViricides' NV-387 oral gummies, if successful, could provide a convenient, orally administered treatment that is easier to distribute in resource-limited settings compared to traditional infusions. This could significantly improve outbreak response and save lives, especially in remote areas. Additionally, the broad-spectrum antiviral platform may offer a rapid response to future viral threats.